BiotechTube

Esomeprazole + Aspirin + Rofecoxib

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Barrett's Esophagus

Conditions

Barrett's Esophagus

Trial Timeline

Apr 1, 2002 → Jun 1, 2003

NCT ID
NCT00637988

About Esomeprazole + Aspirin + Rofecoxib

Esomeprazole + Aspirin + Rofecoxib is a approved stage product being developed by AstraZeneca for Barrett's Esophagus. The current trial status is completed. This product is registered under clinical trial identifier NCT00637988. Target conditions include Barrett's Esophagus.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00637988ApprovedCompleted

Competing Products

3 competing products in Barrett's Esophagus

See all competitors
ProductCompanyStageHype Score
Esomeprazole + LansoprazoleAstraZenecaApproved
85
Esomeprazole MagnesiumAstraZenecaApproved
85
ChemotherapyPacific BiosciencesPre-clinical
15

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85